InflaRx Analyst Price Targets - Benzinga

InflaRx NV

IFRXNASDAQ

Trade with Public

Trade with Public

$2.16

0.031.41%

At close: Sep 1, 5:00 PM EST

$2.20

0.041.85%

After Hours: 7:44 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Compare Options Stock Report

InflaRx Analyst Price Targets

Wall Street analyst price targets and consensus rating for InflaRx (IFRX).

Price Target Range — 13 Quarters

Analyst Consensus — 6 Analysts

1S.Buy

4Buy

1Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$9Upside to Avg. PT+299.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$4→$6
May 13, 2026	Raymond James	Ryan Deschner	Upgrade	Outperform→Strong Buy	$7→$9
May 11, 2026	HC Wainwright & Co.	Matthew Keller	PT Raise	Buy	$6→$8
May 11, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$2→$4
Apr 21, 2026	Guggenheim	Yatin Suneja	Maintained	Buy	$14
Mar 20, 2026	Guggenheim	Yatin Suneja	PT Cut	Buy	$22→$14
Dec 30, 2025	HC Wainwright & Co.	Matthew Keller	Maintained	Buy	$6
Dec 3, 2025	Leerink Partners	Joseph Schwartz	Downgrade	Outperform→Market Perform	$5→$2
Nov 10, 2025	Guggenheim	Yatin Suneja	PT Raise	Buy	$10→$22
Sep 2, 2025	HC Wainwright & Co.	Matthew Keller	Assumes	Buy	$6
May 29, 2025	Oppenheimer	Andreas Argyrides	PT Cut	Outperform	$6→$3
May 8, 2025	Oppenheimer	Andreas Argyrides	Initiate	Outperform	$6
Apr 29, 2025	Cantor Fitzgerald	Steven Seedhouse	Initiate	Overweight	$10
Mar 26, 2025	Guggenheim	Yatin Suneja	PT Raise	Buy	$7→$10
Mar 21, 2025	HC Wainwright & Co.	Edward White	Maintained	Buy	$8
Mar 7, 2025	HC Wainwright & Co.	Edward White	Maintained	Buy	$8
Jan 16, 2025	HC Wainwright & Co.	Edward White	Maintained	Buy	$8
Dec 20, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$8
Nov 15, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$8
Nov 11, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$8

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6

Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.

Benzinga Newsdesk

PRO
Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9

Raymond James analyst Ryan Deschner upgrades InflaRx (NASDAQ:IFRX) from Outperform to Strong Buy and raises the price target from $7 to $9.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8

HC Wainwright & Co. analyst Matthew Keller maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $6 to $8.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4

Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $2 to $4.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on InflaRx, Maintains $14 Price Target

Guggenheim analyst Yatin Suneja reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $14 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on InflaRx, Lowers Price Target to $14

Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $22 to $14.

Benzinga Newsdesk